Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
From a report I read back in late July: ATNM was spending around $10M a quarter; which gave them about a 7 quarter runway with the existing cash, at current burn rate of expenses. I`ve not looked for an updated report since the latest trials release a few days back. Would think they get some FDA go-ahead approvals, they will have to raise cash to move forward.
My understanding was that they have enough money to last well into next year. Am I correct?
This stock should be at $ 12.00 with its future potential and small float.
Investors are expecting management to issue shares in the future. What we need to here is that management will not issue more shares and expect the company to fund operations with their pipeline.
I wish I could say it is just the last few days that has me frustrated. Last few years is more like it. There is so much potential here, yet hardly anyone is taking notice. What is it going to take?
Maybe so. The action over the last two days has me frustrated. Get great news and the price falls. Manipulation it looks like to me. Maybe for an eventual good reason. Idk.
I wonder if a larger suitor is knocking our price down to get a better price on buy out?
Pfizer just bought out a small pharmaceutical company. ATNM could be next if they receive an offer they cannot refuse.
Actinium Pharmaceuticals, Inc. Announces Greater Difference of Approximately 5x for Iomab-B vs Control Arm in the Number of Patients Potentially Evaluable for the Primary Endpoint of the Pivotal Phase 3 SIERRA Trial at the 63rd ASH Annual Meeting
https://www.barrons.com/articles/actinium-pharmaceuticals-inc-announces-greater-difference-of-approximately-5x-for-iomab-b-vs-control-arm-in-the-number-of-patients-potentially-evaluable-for-the-primary-endpoint-of-the-pivotal-phase-3-sierra-trial-at-the-63rd-ash-annual-meeting-01639398922
Lowest 12 month target is $ 26.00. Just hold.
I agree. For a company with so much going for it, I hope to see improvement in the sp soon!
Why, why, why
Why does the share price only know one direction?
Downward direction!
I'm in ATNM since Mai 2018. Never sold one share and i'm down 49%. That's a good investment! NOTLOL
Some tax selling may be happening causing some weakness as traders will take a tax write off now and rebuy shares next year probably at lower prices.
I like your thinking. Unfortunately due to lack of dry powder, I will just have to hold what I have till either b/o or approval. Wish I could establish a trading position in both ATNM and NWBO!
A buyout is always possible with a successful cancer related trail. It will happen if they get an offer they cannot refuse.
The phase three trail was impressive. They have the cash to move forward. It will be at least a year before any progress towards FDA approval. Several analysts have one year targets from $ 26.00 to $38.00. The best way to do his is to set up a core position below $ 8.00. Then trade some shares around the core position to help reduce the cost of the core position. Sit with the core position and give it one year. Good luck and stay safe !!!!
Is a buy out our only hope at this point?? Their pipeline doesn’t seem to impres Wall Street?
Yes, it’s sad because there is so much potential for this company with such a relatively small float and a nice pipeline.
It looks like the traders will keep doing what they have been doing, trading shares in a range, until the trade stops working.
Not sure why there’s no breakout today? Any insights? (For anyone)
Does ASH impose a quiet period or can we still see some company news between now and ASH??
Agreed that it will take regulatory approval to reach 50/sh but I hope we can at least reach 20 with good news/ presentations before the end of the year. With such a small float, this stock is coiled for a spike.
with what is it only 11-14 Million shares outstanding?? Someone has a target price on this of over $50/sh... but for me, thats ONLY after approval...
But, with the end of the PH 3 now into mid 2022, results maybe 3rd qtr, then some time to submit the NDA??
Not surprised its not really doing anything at the moment for its not something really 'sexy' thats going to catch the markets attention like say a Sava or AVXL (alzheimers)
Probably a very accurate description of what’s happening. Hopefully we climb again soon!
My guess the shares are heavily shorted in small time periods to try to drive the price down and then cover, and repeat, repeat, repeat. Just a guess. The share price is definitely being manipulated. Upside targets are very high with a small float.
Drives me crazy that this hasn’t exploded in price yet. Where’s the downside? Low float, promising pipeline? I guess more buying opportunities…
I’m sure you’ll make good money by year’s end at that price. Hopefully it gives you another chance and then we can get out of the 7’s forever!
I was trying to buy shares at 7.70 to 7.75. I could not get an executed fill order.
There should be a firm bottom in by now. Hopefully we can kiss the 7’s goodbye!
My guess another run up is about to happen soon, maybe to $ 11.00.
I agree- not selling until above 18.
Just traders playing games. Has no value to my long term position.
Still can’t figure out the general pull back this week? Hopefully, just a breather before the bigger climb over October.
Wow, hopefully in a long line of good news for Q4! Thank you!
NEW YORK, Oct. 1, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company"), a leader in the development of targeted radiotherapies for patients with unmet needs, today announced that two abstracts featuring targeted radiotherapies in combination with CD47 antibody immunotherapy for solid tumor and hematologic indications have been accepted for presentation at the 36th Annual Meeting of the Society for Immunotherapy for Cancer (SITC 2021). Actinium's abstract titles and presentation logistics are as follows:
(PRNewsfoto/Actinium Pharmaceuticals, Inc.)
(PRNewsfoto/Actinium Pharmaceuticals, Inc.)
Title: Enhancement of the anti-tumor effects of CD47 blockade in solid tumors by combination with targeted radioimmunotherapy
Poster Number: 589
Location: Poster Hall
Dates and Times: 11/12/2021 - 11/14/2021, 7:00 am - 5:00 pm
Title: Anti-CD33 actinium-225 targeted radioimmunotherapy enhances the biologic activity of anti-CD47 antibody immunotherapy in preclinical models of acute myeloid leukemia
Poster Number: 590
Location: Poster Hall
Dates and Times: 11/12/2021 - 11/14/2021, 7:00 am - 5:00 pm
Sandesh Seth, Actinium's Chairman and CEO, said, "We are excited to highlight our latest R&D efforts focused on combinations of actinium-225 based targeted radiotherapies with CD47 immunotherapies, which has emerged as one of the most active targets in immunotherapy drug development of late, in solid tumors and blood cancers. We are thrilled that our abstracts, which are a product of our enhanced R&D capabilities, have been accepted at SITC. This body of work stemmed from our AWE technology platform, R&D capabilities in immuno-oncology and new laboratory facilities. We've highlighted our intention to move into solid tumor indications and immunotherapy combinations outside of the solid tumor work we are doing with our partner Astellas, so it is incredibly exciting to unveil our first initiatives in these areas at SITC. We look forward to presenting data from our work at the conference and continuing to be at the front lines of targeted radiotherapy development leveraging our deep technical knowledge, supply chain and clinical capabilities."
Story continues
Agreed wholeheartedly. Back up the truck!
They are giving you a second gift, a chance to buy cheaper shares. Good luck to all !!! The first gift was when the stock dipped below $ 6.00 PER SHARE.
- Dr. Helen Kotanides Vice President, Translational Research and Preclinical Development with 25 years of immunotherapy and biologics R&D expertise
- Dr. Monideepa Roy, Vice President, Corporate Development - R&D adds company building, research management and oncology R&D experience
NEW YORK, Sept. 27, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company"), a leader in the development of targeted radiotherapies for patients with unmet needs, today announced multiple updates on its R&D capabilities. Actinium recently completed expansion of its New York City based research facilities to focus on the development of targeted radiotherapies for solid tumors and blood cancers and to investigate novel radiotherapy combinations with checkpoint inhibitors. Actinium has more than doubled its laboratory footprint and expanded its R&D capabilities. In addition to infrastructure, Actinium has increased its R&D team to include scientists with expertise across cancer biology, immunology, radiation sciences and chemistry including the appointment of Helen Kotanides, Ph.D., as Vice President, Translational Research and Preclinical Development and Monideepa Roy, Ph.D., as Vice President, Corporate Development - R&D to its R&D leadership team.
I have a bit to go to reach the green (11.50) but I think we’ll get there before the end of the year (and then some!). Buy out after all the results and hopefully fanfare next year. I’m hoping for achieving 1 bn market cap on sale.
Same to you. The price just got back to my average, $9.43. So I’m finally in the green. Plan to stay there! Hoping for a nice buy out soon.
It’s good to see others patiently standing by like myself. Best of luck and hopefully all of our patience will pay off!
A great day and week. Been in their stock about 2 years. Excited for upcoming weeks and months.
Autocorrect- hoo
Come on! Let’s hit 10 today! Will set up for even greater start next week.
Major breakout. Good luck to all !!!!
Been a long ride, and now it appears it will be a bit longer with the news that they just enlisted their last participant..
Won't be surprised if it dips back towards $6 once the effect of the news fades away...
But like many a things, its the 'end game' that matters.
And oft requires a lot more patience than first expected (smile)
Also pretty ironic as I live in the country (lots of tough rows to tow)
Lol! Thank you! I’m quite good at malaprop s!
Pharmboy46......please explain exactly how you would "hoe a road". Seems difficult, that asphalt can be hard LOL. The correct saying is "tough row to hoe", as in a row of crops......You're welcome.
Followers
|
161
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
2833
|
Created
|
04/17/13
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |